Welcome to our dedicated page for Zomedica SEC filings (Ticker: ZOMDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Zomedica Corp. (ZOMDF) filings with the U.S. Securities and Exchange Commission, along with AI-generated summaries to help interpret the information. Zomedica is an animal health company focused on diagnostic, therapeutic, and monitoring devices for equine and companion animals, and its SEC filings offer detailed insight into how it reports financial performance, risks, and strategic priorities.
Investors can use this page to review annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include segment discussions for diagnostics, therapeutic devices, and development services, as well as commentary on consumable and capital revenue, margins, liquidity, and operating expenses. Current reports on Form 8-K, such as the filing dated November 4, 2025 referencing a press release on quarterly results, disclose material events and financial updates between regular reporting periods.
The platform also surfaces proxy statements and other governance-related documents, where available, and Form 4 insider transaction reports that show purchases and sales by directors and officers. These documents can be important for understanding executive incentives and ownership changes.
AI-powered tools on this page summarize lengthy filings, highlight key sections, and explain complex accounting or risk disclosures in plain language. Real-time connections to the SEC’s EDGAR system help ensure new filings appear promptly, so users can quickly locate the latest 10-K, 10-Q, 8-K, and Form 4 documents for Zomedica. This structure allows both individual and professional investors to navigate Zomedica’s regulatory history and evaluate its reported progress in animal health diagnostics and therapeutics.
Zomedica Corp. reported that COO Blair Anthony K received a grant of options to buy 500,000 shares of Common Stock on August 5, 2026, with an exercise price of $0.09 per share and an expiration date of August 4, 2036. One quarter of the options vest on the first anniversary of the grant date, with the remaining options vesting in equal monthly installments until fully vested on August 4, 2030, leaving a reported holding of 500,000 options after the grant.
Zomedica Corp. granted its General Counsel, Karen DeHaan‑Fullerton, 250,000 options to buy common stock at an exercise price of $0.09 per share, expiring on August 4, 2036. One quarter vests on the first anniversary of grant, then 1/48 vests monthly until fully vested by August 4, 2030, leaving 250,000 options held directly after the grant.
Zomedica Corp. reported that Sr Vice President, Sales Russell Kevin Klass received a grant of 250,000 options to buy Common Stock on August 5, 2026, with a conversion or exercise price of 0.0900 per share and an expiration date of August 4, 2036.
The options vest 25% on the first anniversary of the grant date, then in equal monthly installments until fully vested on August 4, 2030. Following this award, he holds 250,000 options directly.
Zomedica reported record second-quarter 2026 revenue of $9.5 million, up 37% from $7.0 million a year earlier, marking its 22nd consecutive quarter of year-over-year revenue growth. Revenue for the first half of 2026 reached $18.3 million, a 36% increase. Growth was broad-based, led by Diagnostics revenue of $1.4 million (up 77%), Therapeutic Devices revenue of $6.8 million (up 9%), and Development Services revenue of $1.4 million in the quarter.
By product category, consumables generated $6.6 million in Q2 revenue (up 26%), capital sales were $1.9 million (up 11%), and engineering services contributed $1.0 million. Gross margin was 64% in the quarter and 63% year-to-date. Operating expenses fell 20% to $10.1 million, with double-digit declines across research and development, selling and marketing, and general and administrative costs.
Net loss narrowed to $3.8 million from $7.4 million, and Adjusted Non-GAAP EBITDA loss improved to $2.3 million from $5.5 million. For the first half, net loss was $8.3 million, significantly lower than $71.2 million in 2025, which included large impairment charges. Cash burn decreased 38% to $3.4 million, the lowest non-year-end level on record, and liquidity stood at $44.1 million in cash, cash equivalents, and available-for-sale securities as of June 30, 2026.
Zomedica Corp., a veterinary health company, reported Q2 2026 net revenue of 9,512 (thousands of U.S. dollars), up from 6,964 a year earlier. Gross profit increased to 6,041, while operating loss narrowed to 4,083 and net loss to 3,765.
For the first six months of 2026, net revenue rose to 18,311 from 13,464, and net loss improved to 8,299 from 71,207, reflecting the absence of prior-year impairment charges of 55,833 for goodwill and intangible assets and 1,981 for property and equipment. General and administrative, research and development, and selling and marketing expenses all declined year over year.
Therapeutic Devices remained the largest segment with six‑month revenue of 12,575, while Diagnostics contributed 2,351 and Development Services 3,385. At June 30, 2026, cash and cash equivalents were 7,194 and available-for-sale securities 36,940, supporting shareholders’ equity of 107,284 against total liabilities of 10,863.
Zomedica Corp. reported the results of its June 10, 2026 annual shareholder meeting. Shareholders elected eight directors to one-year terms and ratified Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ended December 31, 2026.
Shareholders approved an amendment to the company’s By-Laws regarding quorum requirements for adjourned shareholder meetings, with 123,410,315 votes for and 105,771,772 against. However, the non-binding advisory vote on executive compensation failed, with 99,891,977 votes for and 129,290,109 against, while 200,401,613 were broker non-votes.
Zomedica Corp. senior vice president of sales Russell Kevin Klass reported an open-market purchase of 104,000 shares of common stock at $0.103 per share through a spouse account, classified as indirect ownership. A separate holding entry shows he directly owns 6,001,000 common shares after the reported transactions.
Director Johnny D. Powers of Zomedica Corp. reported purchasing a total of 200,000 shares of common stock at $0.1030 per share in three non-derivative transactions described as purchases in open market or private transactions.
After these purchases, he directly holds 4,425,000 shares of Zomedica common stock. The filing indicates these trades were not made under a Rule 10b5-1 trading plan.
Zomedica Corp. reports that Sr. Vice President, Sales, Russell Kevin Klass purchased an aggregate 216,899 shares of common stock, without par value, in three open-market transactions at prices between $0.1050 and $0.1070 per share. Following these purchases, he directly holds 6,001,000 common shares.
Zomedica Corp. director Johnny D. Powers reported open-market purchases of company common stock. He bought a total of 300,000 shares in two transactions, acquiring 200,000 shares at $0.106 per share and 100,000 shares at $0.105 per share. These are direct holdings in non-derivative common stock.